港股異動 | 裕元集團(0551.HK)升近5% 11月銷售跌幅收窄 獲機構唱好
格隆匯12月14日丨裕元集團(0551.HK)報17.2港元,漲4.6%,暫成交1873萬港元,總市值277.3億港元。裕元集團10日公佈,公司11月綜合經營收益淨額(即相當於總銷售額減銷售折扣及銷售退貨)為7.29億美元,按年下跌15.7%。今年首十一個月,綜合累計經營收益淨額為76.2億美元,按年下跌17.6%。花旗發研報稱,11月銷售同比跌15.7%,較10月跌11.6%,但優於第三季19.6%的跌幅。該股股價過去兩週下跌6%,反映復甦緩慢的因素。該行仍然視集團為表現跑輸市場的大中華出口商中的首選,認為明年環球消費將復甦。維持其“買入”評級,目標價23港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.